Herein, we report the largest real-world study of ibrutinib in TN CLL patients with TP53 abnormalities, confirming the efficacy of con- tinuous ibrutinib in unselected patients with this poor prognostic and predictive aberration who are treated in the clinical practice.
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study
Quaglia, Francesca Maria;
2021-01-01
Abstract
Herein, we report the largest real-world study of ibrutinib in TN CLL patients with TP53 abnormalities, confirming the efficacy of con- tinuous ibrutinib in unselected patients with this poor prognostic and predictive aberration who are treated in the clinical practice.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
